MORE THAN 70 COMPANIES CURRENTLY CLAIM TO MANUFACTURE PEPTIDE-BASED THERAPEUTICS

The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service pr